Goldsmith SJ - Search Results

1

Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.

Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Kostakoglu L, et al. Among authors: goldsmith sj. Cancer. 2002 Feb 15;94(4):879-88. Cancer. 2002. PMID: 11920454 Free article. Clinical Trial.

2

PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. Kostakoglu L, et al. Among authors: goldsmith sj. J Nucl Med. 2002 Aug;43(8):1018-27. J Nucl Med. 2002. PMID: 12163626 Free article.

3

18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.

Kostakoglu L, Goldsmith SJ. Kostakoglu L, et al. Among authors: goldsmith sj. J Nucl Med. 2003 Feb;44(2):224-39. J Nucl Med. 2003. PMID: 12571214 Free article. Review.

4

Clinical role of FDG PET in evaluation of cancer patients.

Kostakoglu L, Agress H Jr, Goldsmith SJ. Kostakoglu L, et al. Among authors: goldsmith sj. Radiographics. 2003 Mar-Apr;23(2):315-40; quiz 533. doi: 10.1148/rg.232025705. Radiographics. 2003. PMID: 12640150 Review.

5

Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma.

Leonard JP, Siegel JA, Goldsmith SJ. Leonard JP, et al. Among authors: goldsmith sj. Cancer Invest. 2003 Apr;21(2):241-52. doi: 10.1081/cnv-120016421. Cancer Invest. 2003. PMID: 12743990 Review.

6

PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.

Kostakoglu L, Goldsmith SJ. Kostakoglu L, et al. Among authors: goldsmith sj. J Nucl Med. 2004 Jan;45(1):56-68. J Nucl Med. 2004. PMID: 14734674 Free article. Review.

7

The role of FDG-PET imaging in the management of lymphoma.

Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ. Kostakoglu L, et al. Among authors: goldsmith sj. Clin Adv Hematol Oncol. 2004 Feb;2(2):115-21. Clin Adv Hematol Oncol. 2004. PMID: 16163171 Review.

8

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.

Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, Niesvizky R, Shore T, Schuster MW, Stewart P, Vallabhajosula S, Goldsmith SJ, Leonard JP. Dosik AD, et al. Among authors: goldsmith sj. Cancer. 2006 Feb 1;106(3):616-22. doi: 10.1002/cncr.21606. Cancer. 2006. PMID: 16362977 Free article.

9

Lymphoma imaging: nuclear medicine.

Kostakoglu L, Goldsmith SJ. Kostakoglu L, et al. Among authors: goldsmith sj. Cancer Treat Res. 2006;131:363-412. doi: 10.1007/978-0-387-29346-2_13. Cancer Treat Res. 2006. PMID: 16704177 Review. No abstract available.

10

FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.

Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, Chandramouly A, Verma S, Kothari P, Coleman M. Kostakoglu L, et al. Among authors: goldsmith sj. Cancer. 2006 Dec 1;107(11):2678-87. doi: 10.1002/cncr.22276. Cancer. 2006. PMID: 17063502 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

229 results

Search Page

Filters